Combination treatment with immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated overall survival benefit for patients with melanoma that has spread to the brain, according to phase II study results published in The Lancet Oncology by researchers at MD Anderson Cancer Center.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
